Lung Specialists



Lawrence B Marks, MD

Chairman of the Department of Radiation Oncology
University of North Carolina, Chapel Hill School of Medicine
  • Chairman of the Department of Radiation Oncology
  • Professor of Radiation Oncology
  • Master Clinician Teacher Award
  • America’s Top Doctors

Dr. Larry Marks’ particular interests include clinical trials in breast and lung cancer, as well as in enhancing our understanding of the mechanisms behind radiation associated normal issue injury.  His work assesses the use of advanced technologies to improve the therapeutic ratio for patients with cancers of the breast and lung. He is also interested in human factors engineering as a means to improve safety in the radiation oncology clinic



Kenneth Rosenweig, M.D.

Chairman of the Department of Radiation Oncology
Mount Sinai School of Medicine 

Dr. Rosenzweig is a pioneer in the development of innovative methods for the delivery of precise doses of radiation to lung tumors during certain points in the respiration cycle, allowing physicians to safely increase the radiation dose, shorten treatment and spare healthy tissue. He has also worked to incorporate positron emission tomography (PET), an imaging procedure that produces advanced biological images of the body, into the radiation treatment.



Stephen M. Hahn, M.D.
Henry K. Pancoast Professor, Radiation Oncology
Chair, Department of Radiation Oncology
Director, Photodynamic Therapy Program
Co-Program Leader, Radiation Biology
PennMedicine
University of Pennsylvania

Dr. Hahn is a Professor and Chair of the Department of Radiation Oncology at the Abramson Cancer center. He is an active researcher in developmental therapeutics, Dr. Hahn's efforts focus on Photo Dynamic Therapy (PDT). Dr. Hahn has recently reported the results of a Phase I study of the farnesyltransferase inhibitor (FTI) L-778,123 and radiotherapy for patients with locally advanced lung cancer and head and neck cancer. Significant antitumor responses were reported in patients with lung cancer. Dr. Hahn's clinical practice is dedicated to treating patients with lung cancer, sarcoma, prostate cancer, and mesothelioma.




Feng-Ming (Spring) Kong, MD, PhD, FACR

Professor of Radiation Oncology and Medical & Molecular Genetics
Director of Clinical Research/Clinical Trials, Radiation Oncology
Co-Leader of Thoracic Oncology Program, Simon Cancer Center
Indiana University School of Medicine, Indiana University 


Dr. Kong completed a residency of radiation oncology from Washington University in St. Louis, an internship at the University of Vermont, and a postdoctoral fellowship at Duke University. She received her medical degrees from Fudan University, Shanghai, and also holds a master in Clinical Trial Design and Data Analysis from the University of Michigan. Dr. Kong has 25 years’ experience in radiation therapy for lung cancer, served as the lead of thoracic radiation oncology research in University of Michigan Hospitals and Ann Arbor VA for 10 years, and as an expert panelist of practice appropriateness of American College of Radiology (ACR) and the national comprehensive cancer network guideline (NCCN) and in lung cancer for 5 years.  Dr. Kong received many awards including NIH R21/R01.  has over 150 peer reviewed, invited journal publications and invited book chapters, and over 100 invited lectures. She has served a manuscript reviewer for over 20 journals and served as a member of editorial board of several radiation journals, such as a senior associate editor the international journal radiation oncology, biology and physics, currently is an editorial board member of the Journal of Clinical Oncology (JCO).  Dr. Kong is the national Principal Investigator of RTOG1106, a randomized trial on mid-treatment PET-guided individualized adaptive treatments.  Dr. Kong is committed to apply the knowledge in molecular markers and advanced technology to personalize treatment in patients with lung cancer and other cancers.